Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116824 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Hye Ryun Kim und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Yonsei Cancer Center, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Quinolines, Phenylurea Compounds, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Merck Sharp and Dohme United Kingdom, Eisai Canada.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Yonsei Cancer Center, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: nobelg@yuhs.ac.
- Institut Català d'Oncologia L'Hospitalet, and Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.
- CHU Timone, Marseille, France.
- UCLA Medical Center, Los Angeles, CA, USA.
- Gustave Roussy, Villejuif, France.
- Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Förderung
- Merck Sharp and Dohme United Kingdom
- Eisai Canada
Zitieren
APA
Kim, H. R., Oliva, M., Salas, S., Wong, D. J., Even, C., Kim, J. W., Kang, M., Wu, S. Y., Lauche, O., Ahn, M. J., Yang, M. H., Lien, M. Y., Metcalf, R., Clatot, F., McGrath, M., Webster, M., Assaf, J. D., Rivas, A. S., Bernsdorf, M., …, & Harrington, K. (2026). Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116824
Vancouver
Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, et al. Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116824
BibTeX
@article{Kim2026,
author = {Kim, Hye Ryun and Oliva, Marc and Salas, Sebastien and Wong, Deborah J and Even, Caroline and Kim, Ji-Won and Kang, Minsu and Wu, Shang-Yin and Lauche, Olivier and Ahn, Myung-Ju and Yang, Muh-Hwa and Lien, Ming-Yu and Metcalf, Robert and Clatot, Florian and McGrath, Margaret and Webster, Marc and Assaf, Juan D and Rivas, Ainara Soria and Bernsdorf, Mogens and Billan, Salem and Kaczmar, John and Grose, Derek and Jankowska, Petra and Jelinek, Michael J and Ciuleanu, Tudor Eliade and Vieira, Claudia and Dutcus, Corina and Okpara, Chinyere E and Wang, Guoqing and Bidadi, Behzad and Gumuscu, Burak and Harrington, Kevin},
title = {Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116824}
}
EUVIMED